company background image
5000

Ambalal Sarabhai EnterprisesBSE:500009 Stock Report

Market Cap

₹2.3b

7D

-5.9%

1Y

64.7%

Updated

21 Oct, 2021

Data

Company Financials
500009 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health3/6
Dividends0/6

500009 Overview

Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Ambalal Sarabhai Enterprises
Historical stock prices
Current Share Price₹30.30
52 Week High₹16.60
52 Week Low₹65.00
Beta0.87
1 Month Change-8.32%
3 Month Change-1.46%
1 Year Change64.67%
3 Year Change218.61%
5 Year Change294.53%
Change since IPO109.69%

Recent News & Updates

Shareholder Returns

500009IN PharmaceuticalsIN Market
7D-5.9%-3.7%-2.4%
1Y64.7%19.9%62.6%

Return vs Industry: 500009 exceeded the Indian Pharmaceuticals industry which returned 20% over the past year.

Return vs Market: 500009 matched the Indian Market which returned 63.7% over the past year.

Price Volatility

Is 500009's price volatile compared to industry and market?
500009 volatility
500009 Beta0.87
Industry Beta0.60
Market Beta1

Stable Share Price: 500009 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 500009's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1880n/an/ahttps://www.ase.life

Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company operates through Pharmaceuticals and Electronics segments. It offers products for oncology, infertility, and uro-gynaec areas under the Sarabhai house name; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients.

Ambalal Sarabhai Enterprises Fundamentals Summary

How do Ambalal Sarabhai Enterprises's earnings and revenue compare to its market cap?
500009 fundamental statistics
Market Cap₹2.32b
Earnings (TTM)₹550.21m
Revenue (TTM)₹1.80b

4.2x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
500009 income statement (TTM)
Revenue₹1.80b
Cost of Revenue₹1.06b
Gross Profit₹735.93m
Expenses₹185.72m
Earnings₹550.21m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)7.18
Gross Margin40.96%
Net Profit Margin30.63%
Debt/Equity Ratio35.5%

How did 500009 perform over the long term?

See historical performance and comparison

Valuation

Is Ambalal Sarabhai Enterprises undervalued compared to its fair value and its price relative to the market?

4.22x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 500009's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 500009's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 500009 is good value based on its PE Ratio (4.2x) compared to the Indian Pharmaceuticals industry average (24.9x).

PE vs Market: 500009 is good value based on its PE Ratio (4.2x) compared to the Indian market (21.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 500009's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 500009's PB Ratio (3.1x) is in line with the IN Pharmaceuticals industry average.


Future Growth

How is Ambalal Sarabhai Enterprises forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ambalal Sarabhai Enterprises has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Ambalal Sarabhai Enterprises performed over the past 5 years?

82.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 500009 has a large one-off gain of ₹143.7M impacting its June 30 2021 financial results.

Growing Profit Margin: 500009's current net profit margins (30.6%) are higher than last year (11.1%).


Past Earnings Growth Analysis

Earnings Trend: 500009's earnings have grown significantly by 82.6% per year over the past 5 years.

Accelerating Growth: 500009's earnings growth over the past year (282.3%) exceeds its 5-year average (82.6% per year).

Earnings vs Industry: 500009 earnings growth over the past year (282.3%) exceeded the Pharmaceuticals industry 35.8%.


Return on Equity

High ROE: 500009's Return on Equity (74.5%) is considered outstanding.


Financial Health

How is Ambalal Sarabhai Enterprises's financial position?


Financial Position Analysis

Short Term Liabilities: 500009's short term assets (₹1.2B) do not cover its short term liabilities (₹1.3B).

Long Term Liabilities: 500009's short term assets (₹1.2B) exceed its long term liabilities (₹76.2M).


Debt to Equity History and Analysis

Debt Level: 500009's debt to equity ratio (35.5%) is considered satisfactory.

Reducing Debt: 500009's debt to equity ratio has reduced from 130.1% to 35.5% over the past 5 years.

Debt Coverage: 500009's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: 500009's interest payments on its debt are not well covered by EBIT (1.1x coverage).


Balance Sheet


Dividend

What is Ambalal Sarabhai Enterprises's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 500009's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 500009's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 500009's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 500009's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 500009's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Ambalal Sarabhai Enterprises has no CEO, or we have no data on them.


Leadership Team

Experienced Management: 500009's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: 500009's board of directors are considered experienced (9.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ambalal Sarabhai Enterprises Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Ambalal Sarabhai Enterprises Limited
  • Ticker: 500009
  • Exchange: BSE
  • Founded: 1880
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹2.322b
  • Shares outstanding: 76.63m
  • Website: https://www.ase.life

Number of Employees


Location

  • Ambalal Sarabhai Enterprises Limited
  • Shanti Sadan
  • Mirzapur Road
  • Ahmedabad
  • Gujarat
  • 380001
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 18:04
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.